Year archive

BioLineRx Ltd. — 2026 filings

All 31 regulatory filings released by BioLineRx Ltd. (BLRX) in 2026, sourced directly from the official regulator.

31 Filings

2026 Period

2026 filings (31)

Filing	Released	Lang
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update Regulatory Filings	2026-05-27	English
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update Report Publication Announcement	2026-05-27	English
6-K Report Publication Announcement	2026-05-27	English
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Regulatory Filings	2026-05-24	English
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Report Publication Announcement	2026-05-24	English
6-K Regulatory Filings	2026-05-22	English
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat Regulatory Filings	2026-05-19	Hebrew (modern)
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat Report Publication Announcement	2026-05-19	English
6-K Regulatory Filings	2026-05-19	English
6-K - BioLineRx Ltd. (0001498403) (Filer) Regulatory Filings	2026-04-28	English
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) Regulatory Filings	2026-04-28	English
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) Report Publication Announcement	2026-04-28	English
Immediate Report Regulatory Filings FY 2025	2026-03-29	English
Immediate Report Report Publication Announcement	2026-03-29	English
20-F/A - BioLineRx Ltd. (0001498403) (Filer) Annual Report FY 2025	2026-03-27	English
6-K - BioLineRx Ltd. (0001498403) (Filer) Regulatory Filings	2026-03-26	English
Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) Regulatory Filings	2026-03-26	English
Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) Report Publication Announcement	2026-03-26	English
Reports 2025 Financial Results and Provides Corporate Updat Earnings Release FY 2025	2026-03-23	English
Reports 2025 Financial Results and Provides Corporate Updat Report Publication Announcement	2026-03-23	English
6-K - BioLineRx Ltd. (0001498403) (Filer) Regulatory Filings	2026-03-23	English
20-F - BioLineRx Ltd. (0001498403) (Filer) Annual Report FY 2025	2026-03-23	English
FORM 20-F For the fiscal year ended December 31, 2025 Annual Report FY 2025	2026-03-23	English
FORM 20-F For the fiscal year ended December 31, 2025 Report Publication Announcement	2026-03-23	English
3 - BioLineRx Ltd. (0001498403) (Issuer) Director's Dealing	2026-03-18	English
6-K - BioLineRx Ltd. (0001498403) (Filer) Legal Proceedings Report	2026-02-23	English
In binding arbitration, the arbitrator issued a final award in favor of BioLineRx Ltd. Regulatory Filings	2026-02-23	English
In binding arbitration, the arbitrator issued a final award in favor of BioLineRx Ltd. Report Publication Announcement	2026-02-23	English
Immediate Report Regulatory Filings	2026-01-24	English
Immediate Report Share Issue/Capital Change	2026-01-24	English
S-8 Filing Regulatory Filings	2026-01-23	English

Filings by year

2026 31 filings
2025 52 filings
2024 83 filings
2023 63 filings
2022 74 filings
2021 85 filings
2020 136 filings
2019 90 filings
2018 104 filings
2017 152 filings
2016 106 filings
2015 140 filings
2014 159 filings
2013 168 filings
2012 167 filings
2011 65 filings
2010 1 filing